Trial Profile

An Open Label Extension Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-thalassemia Subjects

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rusfertide (Primary)
Indications Beta-thalassaemia
Focus Adverse reactions; Therapeutic Use
Acronyms TRANSCEND
Sponsors Protagonist Therapeutics

Most Recent Events

04 Feb 2021 Status changed from recruiting to completed.
20 Dec 2020 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
11 Sep 2020 This trial has been completed in Greece , according to European Clinical Trials Database. (2020-04-06)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com